A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs GSK 2857916 (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 09 Oct 2017 Planned End Date changed from 3 Dec 2018 to 3 Jun 2019.
- 09 Oct 2017 Planned primary completion date changed from 3 Dec 2018 to 3 Jun 2019.
- 14 Sep 2017 Planned End Date changed from 12 Nov 2018 to 3 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History